

PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

24 June, 2020

Paradigm wishes to announce that its Chairman Mr Graeme Kaufman tendered his resignation as a Director for personal and health reasons.

Graeme joined the Paradigm Board prior to its IPO / ASX listing and contributed strongly to Paradigm's development and success – reflected in Paradigm recently moving into the ASX 300 on 22 June 2020.

Paradigm's CEO Paul Rennie said, "Graeme has overseen the development of PAR since IPO and I would like to personally thank Graeme for his contribution to Paradigm".

The Paradigm Board has appointed Mr Paul Rennie as its interim Chairman.

This announcement was authorised for release by the Board of Directors.

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email : investorrelations@paradigmbiopharma.com